Abstract
4-Methyl-N-methylcathinone (mephedrone) is a popular new psychoactive substance (NPS) that is structurally related to the parent compound cathinone, the β-keto analogue of amphetamine. Mephedrone appeared on the street drug market as a substitute for 3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy) and was subsequently banned due to the potential health risks associated with its use. Nevertheless, mephedrone continues to be widely consumed among specific populations, with unique patterns of misuse. To date, most information about the biological effects of mephedrone comes from user experiences, epidemiological data, clinical cases, toxicological findings, and animal studies, whilst there are very few data regarding its human pharmacodynamics and pharmacokinetics. This chapter reviews the available published data on patterns of mephedrone use, its acute and chronic effects, and its pharmacokinetic properties. More human research is needed to elucidate the safety, toxicity, and addiction potential of mephedrone and related NPS.
This is a preview of subscription content, log in via an institution.
References
Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, et al. (2014) Khat and synthetic cathinones: a review. Arch Toxicol 88:15–45
Hill SL, Thomas SH (2011) Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 49:705–719
Karila L, Megarbane B, Cottencin O, et al. (2015) Synthetic cathinones: a new public health problem. Curr Neuropharmacol 13:12–20
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014) European drug report 2014: trends and developments. http://www.emcdda.europa.eu/system/files/publications/963/TDAT14001ENN.pdf
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2016) 2016 EU drug markets report: strategic overview. http://www.emcdda.europa.eu/publications/eu-drug-markets/2016/strategic-overview
Papaseit E, Farré M, Schifano F, et al. (2014) Emerging drugs in Europe. Curr Opin Psychiatry 27:243–250
United Nations Office on Drugs and Crime (UNODC) (2016) Laboratory and scientific section portals. Synthetic cathinones. https://www.unodc.org/LSS/SubstanceGroup/Details/67b1ba69-1253-4ae9-bd93-fed1ae8e6802
Brunt TM, Poortman A, Niesink RJ, et al. (2011) Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25:1543–1547
Van Hout MC, Bingham T (2012) “A costly turn on”: patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy 23:188–197
Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42
Deluca P, Schifano F, Davey Z, et al. (2009) Mephedrone report. Institute of Psychiatry, King’s College London, London http://www.psychonautproject.eu
Measham F, Moore K, Newcombe Z, et al. (2010) Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 10:14–21
Winstock AR, Mitcheson L, Marsden J (2010) Mephedrone: still available and twice the price. Lancet 376(9752):1537
Schifano F, Albanese A, Fergus S, Psychonaut Web Mapping, ReDNet Research Groups, et al. (2011) Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214:593–602
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) European drug report 2015. http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf
Winstock AR (2011a) Drugs survey. MixMag 238:49–59
Advisory Council on the Misuse of Drugs (ACMD) (2015) ACMD report on definitions for the Psychoactive Substances Bill, 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/454039/Definitions_report_final_14_august.pgl
Dick D, Torrance C (2010) Drugs survey. MixMag 225:44–53
Winstock A (2012) Global drug survey. MixMag 251:68–73
Carhart-Harris RL, King LA, Nutt DJ (2011) A web-based survey on mephedrone. Drug Alcohol Depend 118:19–22
Wood DM, Heyerdahl F, Yates CB, et al. (2014) The European Drug Emergencies Network (Euro-DEN). Clin Toxicol (Phila) 52:239–241
Public Health England (2015) Adult substance misuse statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April 2014 to 31 March 2015. Public Health England, London https://www.ndtms.net/Publications/downloads/Adult%20Substance%20Misuse/adult-statistics-from-the-national-drug-treatment-monitoring-system-2014-2015.pdf
Hockenhull J, Murphy KG, Paterson S (2016) Mephedrone use is increasing in London. Lancet 387:1719–1720
United Nations Office on Drugs and Crime (UNODC) (2015) World drug report 2015. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2011) Report on the risk assessment of mephedrone in the framework of the council decision on new psychoactive substances. http://www.emcdda.europa.eu/system/files/publications/571/TDAK11001ENC_WEB-OPTIMISED_FILE_280269.pdf
Van Hout MC (2014) An Internet study of user’s experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). J Psychoactive Drugs 46:273–286
Psychonaut Web Mapping Research Group (2009) Mephedrone report. Institute of Psychiatry, King’s College London, London http://194.83.136.209/documents/reports/
The Vaults of Erowid (2016) https://www.erowid.org/chemicals/4_methylmethcathinone/4_methylmethcathinone.shtml
Péterfi A, Tarján A, Horváth GC, et al. (2014) Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Anal 6:825–831
Bourne A, Reid D, Hickson F, Torres-Rueda S (2015) “Chemsex” and harm reduction need among gay men in South London. Int J Drug Policy 26:1171–1176
Daskalopoulou M, Rodger A, Phillips AN, et al. (2014) Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 1:e22–e31
McCall H, Adams N, Mason D, et al. (2015) What is chemsex and why does it matter? BMJ 351:h5790
Hope VD, Cullen KJ, Smith J, et al. (2016) Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? Euro Surveill 21(19). doi:10.2807/1560-7917.ES.2016.21.19.30225
Dargan PI, Sedefov R, Gallegos A, Wood DM (2011) The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 3:454–463
Russo R, Marks N, Morris K, et al. (2012) Life-threatening necrotizing fasciitis due to ‘bath salts’ injection. Orthopedics 35:e124–e127
Winstock AR, Mitcheson LR, Deluca P, et al. (2011b) Mephedrone, new kid for the chop? Addiction 106:154–161
Jones L, Reed P, Parrott A (2016) Mephedrone and 3,4-methylenedioxy-methamphetamine: comparative psychobiological effects as reported by recreational polydrug users. J Psychopharmacol (Epub a head)
World Health Organization (WHO) (2014) Mephedrone. Critical Review Report. 36th ECDD (2014) Agenda ítem 4.12. http://www.who.int/medicines/areas/quality_safety/4_12_review.pdf
Green AR, King MV, Shortall SE, et al. (2014) The preclinical pharmacology of mephedrone; not just MDMA by another name. Br J Pharmacol 171:2251–2268
Karch SB (2015) Cathinone neurotoxicity (“The “3Ms”). Curr Neuropharmacol 13:21–25
Gibbons S, Zloh M (2010) An analysis of the ‘legal high’ mephedrone. Bioorg Med Chem Lett 20:4135–4139
Baumann MH, Ayestas Jr MA, Partilla JS, et al. (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203
Baumann MH, Partilla JS, Lehner KR (2013) Psychoactive “bath salts”: not so soothing. Eur J Pharmacol 698:1–5
Saha K, Partilla JS, Lehner KR, et al. (2015) ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40:1321–1331
Simmler LD, Buser TA, Donzelli M, et al. (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470
Simmler LD, Liechti ME (2016) Interactions of cathinone NPS with human transporters and receptors in transfected cells. Curr Top Behav Neurosci (Epub ahead of print)
Zawilska JB (2014) Mephedrone and other cathinones. Curr Opin Psychiatry 27:256–262
Meng H, Cao J, Kang J, et al. (2012) Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol Lett 208:62–68
Shortall SE, Macerola AE, Swaby RT, et al. (2013) Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol 23:1085–1095
Shortall SE, Green AR, Swift KM, et al. (2013) Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br J Pharmacol 168:966–977
Varner KJ, Daigle K, Weed PF, et al. (2013) Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl) 225:675–685
Wright Jr MJ, Angrish D, Aarde SM, et al. (2012) Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One 7:e44652
Papaseit E, Pérez-Mañá C, Mateus JA, et al. (2016) Human pharmacology of mephedrone in comparison to MDMA. Neuropsychopharmacology 41:2704–2713
Karila L, Billieux J, Benyamina A, et al. (2016) The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences. Brain Res Bull 126:61–67
Wood DM, Hill SL, Thomas SH, Dargan PI (2014) Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Test Anal 6:850–860
Farré M, Papaseit E, Pérez-Mañá C, Yubero-Lahoz S, et al. (2014) Pharmacokinetics and pharmacodynamics of mephedrone in humans. Res Adv Psychiatry 1(Suppl 1):19
de Sousa Fernandes Perna EB, Papaseit E, Pérez-Maná C, et al. (2016) Neurocognitive performance following acute mephedrone administration, with and without alcohol. J Psychopharmacol (Epub ahead of print)
Kapitány-Fövény M, Kertész M, Winstock A, et al. (2013) Substitutional potential of mephedrone: an analysis of the subjective effects. Hum Psychopharmacol 28:308–316
Wood DM, Davies S, Greene SL, et al. (2010) Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 48:924–927
Winstock A, Mitcheson L, Ramsey J, et al. (2011c) Mephedrone: use, subjective effects and health risks. Addiction 106:1991–1996
Deluca P, Davey Z, Corazza O, et al. (2012) Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping project. Prog Neuropsychopharmacol Biol Psychiatry 39:221–226
Durham M (2011) Ivory wave: the next mephedrone? Emerg Med J 28:1059–1060
James D, Adams RD, Spears R, National Poisons Information Service, et al. (2011) Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J 28:686–689
Maskell PD, De Paoli G, Seneviratne C, et al. (2011) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35:188 Poster from The International Association of Forensic Toxicology
Nicholson PJ, Quinn MJ, Dodd JD (2010) Headshop heartache: acute mephedrone ‘meow’ myocarditis. Heart 96:2051–2052
Regan L, Mitchelson M, Macdonald C (2011) Mephedrone toxicity in a Scottish emergency department. Emerg Med J 28:1055–1058
Schifano F, Corkery J, Ghodse AH (2012) Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol 32:710–714
Wood DM, Davies S, Puchnarewicz M, et al. (2010) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6:327–330
Barrio P, Gaskell M, Goti J, et al. (2016) Persistent psychotic symptoms after long-term heavy use of mephedrone: a two-case series. Adicciones 28:154–157
Sivagnanam K, Chaudari D, Lopez P, et al. (2013) “Bath salts” induced severe reversible cardiomyopathy. Am J Case Rep 14:288–291
Dickson AJ, Vorce SP, Levine B, et al. (2010) Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 34:162–168
Torrance H, Cooper G (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202:e62–e63
Wikström M, Thelander G, Nyström I, et al. (2010) Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J Anal Toxicol 34:594–598
Martin M, Muller JF, Turner K, et al. (2012) Evidence of mephedrone chronic abuse through hair analysis using GC/MS. Forensic Sci Int 218:44–48
Mazoyer C, Boucher A, Gaillard Y et al (2011) Case report of driving under the influence of drugs (DUID) with mephedrone in France. Poster from Society of Forensic Toxicologists (SOFT) and The International Association of Forensic Toxicologists (TIAFT)
Pedersen AJ, Reitzel LA, Johansen SS, et al. (2013) In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 5:430–438
Aromatario M, Bottoni E, Santoni M, et al. (2012) New “lethal highs”: a case of a deadly cocktail of GHB and Mephedrone. Forensic Sci Int 223:e38–e41
Corkery JM, Schifano F, Ghodse H (2012) Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. In: Gallelli L (ed) Pharmacology. InTech, ISBN: 978-953-51-0222-9. http://www.intechopen.com/books/pharmacology/mephedrone-related-fatalities-in-the-united-kingdom-contextual-clinical-and-practical-issues
Shah SA, Deshmukh NI, Barker J, et al. (2012) Quantitative analysis of mephedrone using liquid chromatography tandem mass spectroscopy: application to human hair. J Pharm Biomed Anal 61:64–69
Cosbey SH, Peters KL, Quinn A, et al. (2013) Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J Anal Toxicol 37:74–82
Adamowicz P, Tokarczyk B, Stanaszek R, et al. (2013) Fatal mephedrone intoxication – a case report. J Anal Toxicol 37:37–42
Burch HJ, Clarke EJ, Hubbard AM, et al. (2013) Concentrations of drugs determined in blood samples collected from suspected drugged drivers in England and Wales. J Forensic Leg Med 20:278–289
Gerace E, Petrarulo M, Bison F, et al. (2014) Toxicological findings in a fatal multidrug intoxication involving mephedrone. Forensic Sci Int 243:68–73
Maas A, Wippich C, Madea B, et al. (2015) Driving under the influence of synthetic phenethylamines: a case series. Int J Leg Med 129:997–1003
Salomone A, Gazzilli G, Di Corcia D, et al. (2016) Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples. Anal Bioanal Chem 408:2035–2042
Adamowicz P, Gieroń J, Gil D, et al. (2016) The prevalence of new psychoactive substances in biological material – a three-year review of casework in Poland. Drug Test Anal 8:64–71
Loi B, Corkery JM, Claridge H, Goodair C, et al. (2015) Deaths of individuals aged 16-24 years in the UK after using mephedrone. Hum Psychopharmacol 30:225–232
Angoa-Pérez M, Kane MJ, Francescutti DM, et al. (2012) Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 120:1097–1107
Angoa-Pérez M, Kane MJ, Briggs DI, et al. (2013) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem 125:102–110
den Hollander B, Rozov S, Linden AM, et al. (2013) Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone. Pharmacol Biochem Behav 103:501–509
Shortall SE, Green AR, Fone KC, et al. (2016) Caffeine alters the behavioural and body temperature responses to mephedrone without causing long-term neurotoxicity in rats. J Psychopharmacol 30:698–706
Ellefsen KN, Concheiro M, Huestis MA (2016) Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metab Rev 1:1–29
Busardò FP, Kyriakou C, Napoletano S, et al. (2015) Mephedrone related fatalities: a review. Eur Rev Med Pharmacol Sci 19:3777–3790
Baciu T, Borrull F, Calull M, et al. (2016) Enantioselective determination of cathinone derivatives in human hair by capillary electrophoresis combined in-line with solid-phase extraction. Electrophoresis 37:2352–2362
de Castro A, Lendoiro E, Fernández-Vega H, et al. (2014) Liquid chromatography tandem mass spectrometry determination of selected synthetic cathinones and two piperazines in oral fluid. Cross reactivity study with an on-site immunoassay device. J Chromatogr A 1374:93–101
Mercolini L, Protti M, Catapano MC, et al. (2016) LC-MS/MS and volumetric absorptive microsampling for quantitative bioanalysis of cathinone analogues in dried urine, plasma and oral fluid samples. J Pharm Biomed Anal 123:186–194
Strano-Rossi S, Anzillotti L, Castrignanò E, et al. (2012) Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, “spice” and stimulants in oral fluid. J Chromatogr A 1258:37–42
Pozo ÓJ, Ibáñez M, Sancho JV, et al. (2015) Mass spectrometric evaluation of mephedrone in vivo human metabolism: identification of phase I and phase II metabolites, including a novel succinyl conjugate. Drug Metab Dispos 43:248–257
Khreit OI, Grant MH, Zhang T, et al. (2013) Elucidation of the Phase I and Phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS2. J Pharm Biomed Anal 72:177–185
Mayer FP, Wimmer L, Dillon-Carter O, et al. (2016) Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol 173:2657–2668
Martínez-Clemente J, López-Arnau R, Carbó M, et al. (2013) Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology (Berl) 229:295–306
Meyer MR, Wilhelm J, Peters FT, et al. (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225–1233
Aarde SM, Angrish D, Barlow DJ, et al. (2013) Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol 18:786–799
Creehan KM, Vandewater SA, Taffe MA (2015) Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90–97
Gatch MB, Taylor CM, Forster MJ (2013) Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones. Behav Pharmacol 24:437–447
Hadlock GC, Webb KM, McFadden LM, et al. (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530–536
Karlsson L, Andersson M, Kronstrand R, et al. (2014) Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin Pharmacol Toxicol 115:411–416
Lisek R, Xu W, Yuvasheva E, Chiu YT, et al. (2012) Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend 126:257–262
Vandewater SA, Creehan KM, Taffe MA (2015) Intravenous self-administration of entactogen-class stimulants in male rats. Neuropharmacology 99:538–545
Motbey CP, Clemens KJ, Apetz N, et al. (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 27:823–836
Shortall SE, Spicer CH, Ebling FJ, et al. (2015) Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone. Addict Biol 21:1127–1139
Dargan PI, Albert S, Wood DM (2010) Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 103:875–879
Bajaj N, Mullen D, Wylie S (2010) Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. BMJ Case Rep 2010. doi:10.1136/bcr.02.2010.2780
Dolengevich-Segal H, Rodríguez-Salgado B, Gómez-Arnau J, et al. (2016) Severe psychosis, drug dependence, and Hepatitis C related to slamming mephedrone. Case Rep Psychiatry 2016:8379562
Uosukainen H, Tacke U, Winstock AR (2015) Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy 26:78–83
Kapitány-Fövény M, Mervó B, et al. (2015) Is there any difference in patterns of use and psychiatric symptom status between injectors and non-injectors of mephedrone? Hum Psychopharmacol 30:233–243
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2010) 2010 Annual report on the state of the drugs problem in Europe. http://www.emcdda.europa.eu/system/files/publications/926/EMCDDA_AR2010_EN_242720.pdf
Food and Drug Administration (FDA) (2010) Draft guidance “assessment of abuse potential of drugs”. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf
Acknowledgments
This work was supported in part by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI11/01961; Red de Trastornos Adictivos-RTA-FEDER RD16/0017/0003 and RD16/0017/0010; Juan Rodes fellowship JR16/00020) and The European Commission (Drugs Policy Initiatives, Justice Programme 2014–2020, Contract no. HOME/2014/JDRU/AG/DRUG/7082, PREDICT Project).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Papaseit, E., Moltó, J., Muga, R., Torrens, M., de la Torre, R., Farré, M. (2016). Clinical Pharmacology of the Synthetic Cathinone Mephedrone. In: Baumann, M.H., Glennon, R.A., Wiley, J.L. (eds) Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences, vol 32. Springer, Cham. https://doi.org/10.1007/7854_2016_61
Download citation
DOI: https://doi.org/10.1007/7854_2016_61
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52442-9
Online ISBN: 978-3-319-52444-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)